

Xultophy® 100/3.6 (insulin degludec and liraglutide injection) – Expanded indication

- On February 27, 2019, the FDA approved Novo Nordisk's <u>Xultophy 100/3.6 (insulin degludec and liraglutide)</u>, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
 - Previously, Xultophy was approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 50 units daily) or Victoza[®] (liraglutide) (less than or equal to 1.8 mg daily).
 - Xultophy is not recommended as first-line therapy for patients who have inadequate glycemic control on diet and exercise because of the uncertain relevance of the rodent C-cell tumor findings to humans.
 - Xultophy is not recommended for use in combination with any other product containing liraglutide or another glucagon-like peptide 1 (GLP-1) receptor agonist.
 - Xultophy is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
 - Xultophy has not been studied in combination with prandial insulin.
- The approval of Xultophy's expanded indication was based on two, 26-week studies in patients with type 2 diabetes inadequately controlled on one or more oral antidiabetic drugs. Study 1 (N = 1,660) was open-label and patients were randomized to Xultophy, Tresiba® (insulin degludec), or Victoza. Study 2 (N = 435) was double-blind and patients were randomized to Xultophy or placebo.
 - In study 1, treatment with Xultophy, Tresiba, and Victoza resulted in a reduction in HbA1c from baseline of 1.81%, 1.35% and 1.21%, respectively. The estimated difference between Xultophy and Tresiba was -0.46% (95% CI: -0.59, -0.34; p < 0.01 for non-inferiority). The estimated difference between Xultophy and Victoza was -0.60% (95% CI: -0.72, -0.47; p < 0.01 for superiority).</p>
 - In study 2, treatment with Xultophy resulted in statistically significant reductions in HbA1c vs. placebo (estimated treatment difference: -0.81%; 95% Cl: -0.98; -0.63; p < 0.01 superiority).
- Xultophy carries a boxed warning for risk of thyroid C-cell tumors.
- The recommended starting dose of Xultophy in patients naïve to basal insulin or GLP-1 receptor agonists is 10 units (10 units of insulin degludec and 0.36 mg of liraglutide) given subcutaneously (SC) once daily.
- The recommended starting dose of Xultophy in patients currently on basal insulin or GLP-1 receptor agonists is 16 units (16 units of insulin degludec and 0.58 mg of liraglutide) given SC once-daily.
 - Xultophy should be administered at the same time each day with or without food.
 - The maximum daily dosage of Xultophy is 50 units (50 units of insulin degludec and 1.8 mg of liraglutide).
 - Xultophy delivers doses from 10 to 50 units with each injection.
 - Refer to the Xultophy drug label for specific titration instructions.



optumrx.com

Optum Rx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

 $All \ Optum^{@} trademarks \ and \ logos \ are \ owned \ by \ Optum, \ Inc. \ All \ other \ brand \ or \ product \ names \ are \ trademarks \ or \ registered \ marks \ of \ their \ respective \ owners.$

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.